Amgen reacquired all rights to sell three drugs worldwide on Dec. 14.
The Thousand Oaks-based biotech giant said it reacquired the rights to Prolia, Vectibix and Xgeva in 48 ccountries from British pharmaceutical company GlaxoSmithKline. The agreement includes large countries like Australia, China and Brazil.
Prolia is designed to raise bone density in people with a history of osteoporosis. Xgeva is used to prevent bone fractures and in patients with tumors that have spread into bones. Vectibix interferes with the growth of cancer cells in patients with metastatic colorectal cancer.
GlaskoSmithKline generated $111 million in 2014 revenue by licensing the drugs from Amgen, according to an Amgen news release.
As part of the agreement, Amgen will make milestone payments to GlaxoSmithKline. Terms of the agreement were not disclosed.
• Contact Philip Joens at [email protected]